Would you offer, and what data would support, the use of an FGFR inhibitor in FGFR3 mutated anaplastic thyroid cancer?

With the lack of effective treatment options for ATC except for BRAFV600E pos subset, every patient should have extended panel NGS and enrolled in trials. With FGFR3 mutation, I would definitely favor enrolling the patient in one of the biomarker (FGFR fusion/mut pos)-specific clinical trials.